Banque Pictet & Cie Sa Ascendis Pharma A/S Transaction History

Banque Pictet & Cie Sa

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	SELL	$104.9 - $126.78 $380,367 - $459,704	-3,626 Reduced 31.2%	7,997 $857,000
Q4 2022 Feb 06, 2023	SELL	$99.42 - $131.97 $364,672 - $484,065	-3,668 Reduced 23.99%	11,623 $0
Q3 2022 Nov 10, 2022	SELL	$84.03 - $110.23 $4,873 - $6,393	-58 Reduced 0.38%	15,291 $1.58 Billion
Q2 2022 Aug 08, 2022	SELL	$78.08 - $117.61 $115,246 - $173,592	-1,476 Reduced 8.77%	15,349 $1.43 Million
Q1 2022 May 04, 2022	BUY	$102.18 - $135.75 $801,704 - $1.07 Million	7,846 Added 87.38%	16,825 $1.98 Million
Q4 2021 Feb 02, 2022	BUY	$127.1 - $169.66 $1.14 Million - $1.52 Million	8,979 New	8,979 $1.21 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.